Industry leaders have given a cautious welcome to the interim ruling to down schedule low-dose CBD, but significant doubts persist over how meaningful the decision will be for patients and manufacturers.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Concern will inevitably focus on the strength of efficacy data required by health authorities for a product to be registered on the Australian Register of Therapeutic Goods (ARTG) and therefore available for sale through pharmacies.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...